• This collaboration offers an integrated solution for customers looking to outsource the development and production of microbial and mammalian-expressed peptide drugs, with scalable options that address the full range of requirements of the product.

OKLAHOMA CITY & TORRANCE, Calif.–(BUSINESS WIRE)–In response to the growing demand for peptide drugs, Cytovance Biologics and PolyPeptide announced a partnership that combines Cytovance’s expertise in microbial and mammalian expression , process development and cGMP manufacturing with PolyPeptide’s complex peptide development and manufacturing capabilities.

This press release contains multimedia. See the full release here: https://www.businesswire.com/news/home/20250113598664/en/

Axel Schleyer, CCO of Cytovance Biologics: Cytovance has supported the development and scaling of microbial and mammalian-expressed biologics for two decades. Combining our strengths with PolyPeptide is exactly what our customers and industry need to support the rapid growth in market demand.

Trishul Shah, PolyPeptide Director of Business Development: With a track record of more than 1,000 therapeutic peptides manufactured, PolyPeptide offers deep peptide development and synthesis capabilities. The collaboration gives customers access to complementary technology portfolios to drive their innovative drug development projects.

The two companies have previously partnered on specific customer projects. The new collaboration expands the partnership to the benefit of drug developers looking for increased capacity, rapid ramp-up, and increased efficiency, helping to drive new peptide products into the clinic. and market.

See the original version on businesswire.com: https://www.businesswire.com/news/home/20250113598664/en/

For Cytovance media inquiries, please contact:
[email protected]
@Cytovance Biologics “ follow us on LinkedIn

For PolyPeptide media inquiries, please contact:
[email protected]
@PolyPeptide “ follow us on LinkedIn

Source: Cytovance Biologics